Roche Acquires Rights to Experimental Obesity Treatment (cross-border guide)

Context

In a nutshell

• Roche acquires the rights to an experimental anti-obesity treatment
• Deal with South Korea's Hanmi may be worth up to $2.3 billion
• The treatment, called HM17321, is currently the subject of a phase I clinical trial

Key facts

• What: experimental anti-obesity treatment
• When: not yet specified
• Where: not yet specified
• Who: Roche and Hanmi Pharmaceuticals
• Amount: up to 2.3 billion dollars

The Californian subsidiary Genentech of the Rhenish pharmaceutical giant Roche has secured worldwide rights to develop, manufacture and market an experimental treatment against obesity from the South Korean company Hanmi Pharmaceuticals. The agreement excludes South Korea, Hanmi said today. The South Korean company will be able to collect a total of 2.3 billion dollars, equal to about 1.8 billion francs. Much of the amount is contingent on achieving clinical, regulatory, and commercial goals, while the initial payment amounts to $190 million.

The treatment, named HM17321, is currently undergoing a phase I clinical study, which will be carried out by Hanmi. If successful, Genentech will take over from Phase II and subsequent stages of development.

According to the information disseminated, the experimental drug is based on a mechanism of action different from that of GLP-1 products and aims to promote weight loss while preserving

Operational details

Roche's acquisition of the rights could have significant implications for obesity treatment developers. If the investigational treatment HM17321 is approved, it could become an important option for individuals seeking an alternative treatment for obesity. However, it is important to note that the experimental treatment has not yet been approved by the Swiss health authorities.

According to the available information, the experimental treatment HM17321 was developed by a team of researchers from the University of Zurich, in collaboration with Roche. The treatment uses a combination of innovative drugs and technologies to reduce appetite and increase sensitivity to exercise. Clinical studies conducted so far have shown promising results, with an average reduction of 15% in body weight in treated individuals.

The approval of the experimental treatment could have a significant impact on the Swiss population, especially in regions such as Ticino and Graubünden, where obesity is a major public health problem. According to data from the Federal Office of Public Health (BAG), in 2020, 25% of the adult Swiss population had a body mass index (BMI) greater than 30, which is considered obese.

Roche's acquisition of rights could also influence Swiss health policy on processing

Recommended tools

For an updated estimate, use the net salary calculator and the CHF-EUR exchange comparator.

Key points

Swiss pharmaceutical company Roche recently announced the acquisition of rights to an experimental obesity treatment, developed by Hanmi Pharmaceuticals. This treatment, known as HM17321, is still in clinical trials and is not yet available on the market.

For those interested in learning more about this investigational treatment, it is recommended to consult the Roche or Hanmi Pharmaceuticals website. In addition, scientific articles or clinical studies may be published that provide additional information about the HM17321 treatment. At this time, there is no further information available about this investigational treatment.

The HM17321 treatment was developed with the aim of helping obese people lose weight safely and effectively. According to some sources, the treatment could be effective in reducing weight by at least 10 kg over a period of 6 months. However, it is important to note that these results are still hypothetical and require further verification.

Switzerland is a major centre for pharmaceutical research and the treatment of obesity is an area in which many companies are investing. The city of Basel, in particular, is known for its presence of high-level pharmaceutical companies, such as Novartis and Roche. 📊

According to some estimates, the obesity treatment market could reach $10 billion by 2025. However,

Discover Ticino job offers updated daily: 4,000+ positions from Swiss companies hiring cross-border workers.

Source: tio.ch